nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—Night blindness—Varenicline—nicotine dependence	0.0351	0.0466	CcSEcCtD
Nefazodone—Varicose vein—Varenicline—nicotine dependence	0.0222	0.0295	CcSEcCtD
Nefazodone—Dysphoria—Varenicline—nicotine dependence	0.0191	0.0254	CcSEcCtD
Nefazodone—Suicide—Varenicline—nicotine dependence	0.0159	0.0212	CcSEcCtD
Nefazodone—Hostility—Varenicline—nicotine dependence	0.0149	0.0198	CcSEcCtD
Nefazodone—Suicide attempt—Varenicline—nicotine dependence	0.0146	0.0194	CcSEcCtD
Nefazodone—Completed suicide—Varenicline—nicotine dependence	0.0141	0.0187	CcSEcCtD
Nefazodone—Libido increased—Varenicline—nicotine dependence	0.0136	0.0181	CcSEcCtD
Nefazodone—Paranoia—Varenicline—nicotine dependence	0.0121	0.0161	CcSEcCtD
Nefazodone—Suicidal ideation—Varenicline—nicotine dependence	0.0118	0.0157	CcSEcCtD
Nefazodone—Scotoma—Varenicline—nicotine dependence	0.0109	0.0145	CcSEcCtD
Nefazodone—Gingivitis—Varenicline—nicotine dependence	0.0105	0.014	CcSEcCtD
Nefazodone—Mydriasis—Varenicline—nicotine dependence	0.0104	0.0138	CcSEcCtD
Nefazodone—Nephrolithiasis—Varenicline—nicotine dependence	0.0103	0.0137	CcSEcCtD
Nefazodone—Accidental injury—Varenicline—nicotine dependence	0.00934	0.0124	CcSEcCtD
Nefazodone—CYP3A7—Xenobiotics—CYP2A7—nicotine dependence	0.00931	0.0437	CbGpPWpGaD
Nefazodone—Ventricular extrasystoles—Varenicline—nicotine dependence	0.00915	0.0122	CcSEcCtD
Nefazodone—Thinking abnormal—Varenicline—nicotine dependence	0.00903	0.012	CcSEcCtD
Nefazodone—Nocturia—Varenicline—nicotine dependence	0.00891	0.0118	CcSEcCtD
Nefazodone—Dysarthria—Varenicline—nicotine dependence	0.00874	0.0116	CcSEcCtD
Nefazodone—Coordination abnormal—Varenicline—nicotine dependence	0.00841	0.0112	CcSEcCtD
Nefazodone—Abnormal dreams—Varenicline—nicotine dependence	0.00817	0.0109	CcSEcCtD
Nefazodone—Eructation—Varenicline—nicotine dependence	0.00812	0.0108	CcSEcCtD
Nefazodone—Salivary hypersecretion—Varenicline—nicotine dependence	0.00802	0.0107	CcSEcCtD
Nefazodone—Photophobia—Varenicline—nicotine dependence	0.00776	0.0103	CcSEcCtD
Nefazodone—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00772	0.0362	CbGpPWpGaD
Nefazodone—Dry eye—Varenicline—nicotine dependence	0.00763	0.0101	CcSEcCtD
Nefazodone—Oesophagitis—Varenicline—nicotine dependence	0.00755	0.01	CcSEcCtD
Nefazodone—Mouth ulceration—Varenicline—nicotine dependence	0.00747	0.00993	CcSEcCtD
Nefazodone—Urine output increased—Varenicline—nicotine dependence	0.00747	0.00993	CcSEcCtD
Nefazodone—Hypertonia—Varenicline—nicotine dependence	0.00724	0.00963	CcSEcCtD
Nefazodone—Mental disability—Varenicline—nicotine dependence	0.00717	0.00953	CcSEcCtD
Nefazodone—Euphoric mood—Varenicline—nicotine dependence	0.0071	0.00944	CcSEcCtD
Nefazodone—Lymphadenopathy—Varenicline—nicotine dependence	0.00703	0.00935	CcSEcCtD
Nefazodone—Polyuria—Varenicline—nicotine dependence	0.00683	0.00908	CcSEcCtD
Nefazodone—CYP3A5—Xenobiotics—CYP2A7—nicotine dependence	0.00673	0.0316	CbGpPWpGaD
Nefazodone—Deafness—Varenicline—nicotine dependence	0.00671	0.00892	CcSEcCtD
Nefazodone—Eczema—Varenicline—nicotine dependence	0.00667	0.00887	CcSEcCtD
Nefazodone—Eye pain—Varenicline—nicotine dependence	0.00664	0.00883	CcSEcCtD
Nefazodone—Injury—Varenicline—nicotine dependence	0.00653	0.00868	CcSEcCtD
Nefazodone—Libido decreased—Varenicline—nicotine dependence	0.00647	0.0086	CcSEcCtD
Nefazodone—Increased appetite—Varenicline—nicotine dependence	0.00638	0.00849	CcSEcCtD
Nefazodone—Visual disturbance—Varenicline—nicotine dependence	0.00633	0.00842	CcSEcCtD
Nefazodone—Thirst—Varenicline—nicotine dependence	0.0063	0.00838	CcSEcCtD
Nefazodone—Arthritis—Varenicline—nicotine dependence	0.00617	0.00821	CcSEcCtD
Nefazodone—Hypoglycaemia—Varenicline—nicotine dependence	0.00615	0.00817	CcSEcCtD
Nefazodone—Cerebrovascular accident—Varenicline—nicotine dependence	0.00612	0.00814	CcSEcCtD
Nefazodone—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.00602	0.0282	CbGpPWpGaD
Nefazodone—Gastrointestinal haemorrhage—Varenicline—nicotine dependence	0.006	0.00798	CcSEcCtD
Nefazodone—Osteoarthritis—Varenicline—nicotine dependence	0.006	0.00798	CcSEcCtD
Nefazodone—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.00595	0.00791	CcSEcCtD
Nefazodone—Migraine—Varenicline—nicotine dependence	0.0059	0.00785	CcSEcCtD
Nefazodone—Affect lability—Varenicline—nicotine dependence	0.0059	0.00785	CcSEcCtD
Nefazodone—Urinary retention—Varenicline—nicotine dependence	0.0057	0.00758	CcSEcCtD
Nefazodone—Mood swings—Varenicline—nicotine dependence	0.00568	0.00756	CcSEcCtD
Nefazodone—Liver function test abnormal—Varenicline—nicotine dependence	0.00554	0.00736	CcSEcCtD
Nefazodone—Dry skin—Varenicline—nicotine dependence	0.0055	0.00731	CcSEcCtD
Nefazodone—Cramp muscle—Varenicline—nicotine dependence	0.0054	0.00718	CcSEcCtD
Nefazodone—Gastritis—Varenicline—nicotine dependence	0.00531	0.00706	CcSEcCtD
Nefazodone—Abdominal distension—Varenicline—nicotine dependence	0.00522	0.00694	CcSEcCtD
Nefazodone—Dysphagia—Varenicline—nicotine dependence	0.00518	0.00689	CcSEcCtD
Nefazodone—Asthma—Varenicline—nicotine dependence	0.00518	0.00689	CcSEcCtD
Nefazodone—Angina pectoris—Varenicline—nicotine dependence	0.00505	0.00671	CcSEcCtD
Nefazodone—Bronchitis—Varenicline—nicotine dependence	0.00499	0.00663	CcSEcCtD
Nefazodone—Pollakiuria—Varenicline—nicotine dependence	0.00479	0.00637	CcSEcCtD
Nefazodone—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00478	0.0224	CbGpPWpGaD
Nefazodone—Erectile dysfunction—Varenicline—nicotine dependence	0.00477	0.00635	CcSEcCtD
Nefazodone—Photosensitivity reaction—Varenicline—nicotine dependence	0.00473	0.00629	CcSEcCtD
Nefazodone—Weight increased—Varenicline—nicotine dependence	0.00472	0.00627	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.00458	0.00609	CcSEcCtD
Nefazodone—Stomatitis—Varenicline—nicotine dependence	0.00451	0.00599	CcSEcCtD
Nefazodone—Conjunctivitis—Varenicline—nicotine dependence	0.00449	0.00597	CcSEcCtD
Nefazodone—Epistaxis—Varenicline—nicotine dependence	0.00436	0.0058	CcSEcCtD
Nefazodone—Sinusitis—Varenicline—nicotine dependence	0.00434	0.00577	CcSEcCtD
Nefazodone—Acetophenazine—DRD2—nicotine dependence	0.00432	0.177	CrCbGaD
Nefazodone—Bradycardia—Varenicline—nicotine dependence	0.00422	0.00562	CcSEcCtD
Nefazodone—Hallucination—Varenicline—nicotine dependence	0.00413	0.00549	CcSEcCtD
Nefazodone—Hypoaesthesia—Varenicline—nicotine dependence	0.00413	0.00549	CcSEcCtD
Nefazodone—Oedema peripheral—Varenicline—nicotine dependence	0.00409	0.00544	CcSEcCtD
Nefazodone—Visual impairment—Varenicline—nicotine dependence	0.004	0.00532	CcSEcCtD
Nefazodone—Erythema multiforme—Varenicline—nicotine dependence	0.00392	0.00522	CcSEcCtD
Nefazodone—Tinnitus—Varenicline—nicotine dependence	0.00387	0.00514	CcSEcCtD
Nefazodone—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00386	0.0181	CbGpPWpGaD
Nefazodone—CYP3A7—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00381	0.0179	CbGpPWpGaD
Nefazodone—ADRA1B—G alpha (12/13) signalling events—FGD1—nicotine dependence	0.00376	0.0176	CbGpPWpGaD
Nefazodone—Chills—Varenicline—nicotine dependence	0.00372	0.00495	CcSEcCtD
Nefazodone—Flatulence—Varenicline—nicotine dependence	0.00356	0.00473	CcSEcCtD
Nefazodone—Dysgeusia—Varenicline—nicotine dependence	0.00354	0.0047	CcSEcCtD
Nefazodone—Back pain—Varenicline—nicotine dependence	0.00349	0.00465	CcSEcCtD
Nefazodone—Muscle spasms—Varenicline—nicotine dependence	0.00347	0.00462	CcSEcCtD
Nefazodone—Vision blurred—Varenicline—nicotine dependence	0.0034	0.00453	CcSEcCtD
Nefazodone—Tremor—Varenicline—nicotine dependence	0.00338	0.0045	CcSEcCtD
Nefazodone—Ill-defined disorder—Varenicline—nicotine dependence	0.00335	0.00446	CcSEcCtD
Nefazodone—ADRA1A—G alpha (12/13) signalling events—FGD1—nicotine dependence	0.00334	0.0157	CbGpPWpGaD
Nefazodone—Anaemia—Varenicline—nicotine dependence	0.00334	0.00444	CcSEcCtD
Nefazodone—Agitation—Varenicline—nicotine dependence	0.00332	0.00441	CcSEcCtD
Nefazodone—Angioedema—Varenicline—nicotine dependence	0.0033	0.00439	CcSEcCtD
Nefazodone—Domperidone—DRD2—nicotine dependence	0.00327	0.134	CrCbGaD
Nefazodone—Malaise—Varenicline—nicotine dependence	0.00326	0.00433	CcSEcCtD
Nefazodone—Vertigo—Varenicline—nicotine dependence	0.00325	0.00432	CcSEcCtD
Nefazodone—Syncope—Varenicline—nicotine dependence	0.00324	0.00431	CcSEcCtD
Nefazodone—Palpitations—Varenicline—nicotine dependence	0.00319	0.00424	CcSEcCtD
Nefazodone—Loss of consciousness—Varenicline—nicotine dependence	0.00317	0.00422	CcSEcCtD
Nefazodone—Cough—Varenicline—nicotine dependence	0.00315	0.00419	CcSEcCtD
Nefazodone—CYP3A7—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00313	0.0147	CbGpPWpGaD
Nefazodone—Convulsion—Varenicline—nicotine dependence	0.00313	0.00416	CcSEcCtD
Nefazodone—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00313	0.0147	CbGpPWpGaD
Nefazodone—Hypertension—Varenicline—nicotine dependence	0.00312	0.00415	CcSEcCtD
Nefazodone—Arthralgia—Varenicline—nicotine dependence	0.00308	0.00409	CcSEcCtD
Nefazodone—Myalgia—Varenicline—nicotine dependence	0.00308	0.00409	CcSEcCtD
Nefazodone—Chest pain—Varenicline—nicotine dependence	0.00308	0.00409	CcSEcCtD
Nefazodone—Anxiety—Varenicline—nicotine dependence	0.00306	0.00408	CcSEcCtD
Nefazodone—Discomfort—Varenicline—nicotine dependence	0.00304	0.00404	CcSEcCtD
Nefazodone—Dry mouth—Varenicline—nicotine dependence	0.00301	0.004	CcSEcCtD
Nefazodone—HTR1A—Monoamine GPCRs—DRD2—nicotine dependence	0.00296	0.0139	CbGpPWpGaD
Nefazodone—Oedema—Varenicline—nicotine dependence	0.00295	0.00392	CcSEcCtD
Nefazodone—HTR2C—Monoamine GPCRs—DRD2—nicotine dependence	0.00294	0.0138	CbGpPWpGaD
Nefazodone—Infection—Varenicline—nicotine dependence	0.00293	0.00389	CcSEcCtD
Nefazodone—Shock—Varenicline—nicotine dependence	0.0029	0.00386	CcSEcCtD
Nefazodone—Thrombocytopenia—Varenicline—nicotine dependence	0.00289	0.00384	CcSEcCtD
Nefazodone—Tachycardia—Varenicline—nicotine dependence	0.00288	0.00383	CcSEcCtD
Nefazodone—Hyperhidrosis—Varenicline—nicotine dependence	0.00285	0.00379	CcSEcCtD
Nefazodone—ADRA1B—Monoamine GPCRs—DRD2—nicotine dependence	0.00282	0.0132	CbGpPWpGaD
Nefazodone—Anorexia—Varenicline—nicotine dependence	0.00281	0.00374	CcSEcCtD
Nefazodone—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00279	0.0131	CbGpPWpGaD
Nefazodone—CYP3A5—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00276	0.0129	CbGpPWpGaD
Nefazodone—Hypotension—Varenicline—nicotine dependence	0.00275	0.00366	CcSEcCtD
Nefazodone—Zuclopenthixol—DRD2—nicotine dependence	0.00274	0.112	CrCbGaD
Nefazodone—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00269	0.00357	CcSEcCtD
Nefazodone—Insomnia—Varenicline—nicotine dependence	0.00267	0.00355	CcSEcCtD
Nefazodone—Dyspnoea—Varenicline—nicotine dependence	0.00263	0.00349	CcSEcCtD
Nefazodone—Somnolence—Varenicline—nicotine dependence	0.00262	0.00348	CcSEcCtD
Nefazodone—Dyspepsia—Varenicline—nicotine dependence	0.0026	0.00345	CcSEcCtD
Nefazodone—Decreased appetite—Varenicline—nicotine dependence	0.00256	0.00341	CcSEcCtD
Nefazodone—HTR2A—Monoamine GPCRs—DRD2—nicotine dependence	0.00256	0.012	CbGpPWpGaD
Nefazodone—Aripiprazole—DRD2—nicotine dependence	0.00253	0.104	CrCbGaD
Nefazodone—Constipation—Varenicline—nicotine dependence	0.00252	0.00335	CcSEcCtD
Nefazodone—Pain—Varenicline—nicotine dependence	0.00252	0.00335	CcSEcCtD
Nefazodone—ADRA1A—Monoamine GPCRs—DRD2—nicotine dependence	0.0025	0.0117	CbGpPWpGaD
Nefazodone—HTR1A—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00249	0.0117	CbGpPWpGaD
Nefazodone—SLC6A4—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00248	0.0117	CbGpPWpGaD
Nefazodone—HTR2C—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00247	0.0116	CbGpPWpGaD
Nefazodone—Feeling abnormal—Varenicline—nicotine dependence	0.00243	0.00323	CcSEcCtD
Nefazodone—Gastrointestinal pain—Varenicline—nicotine dependence	0.00241	0.00321	CcSEcCtD
Nefazodone—Thioproperazine—DRD2—nicotine dependence	0.0024	0.0984	CrCbGaD
Nefazodone—ADRA1B—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00237	0.0111	CbGpPWpGaD
Nefazodone—SLC6A3—Transmission across Chemical Synapses—CHRNB3—nicotine dependence	0.00236	0.0111	CbGpPWpGaD
Nefazodone—Urticaria—Varenicline—nicotine dependence	0.00234	0.00311	CcSEcCtD
Nefazodone—Body temperature increased—Varenicline—nicotine dependence	0.00233	0.0031	CcSEcCtD
Nefazodone—Abdominal pain—Varenicline—nicotine dependence	0.00233	0.0031	CcSEcCtD
Nefazodone—ADRA2A—Monoamine GPCRs—DRD2—nicotine dependence	0.00233	0.0109	CbGpPWpGaD
Nefazodone—CYP3A5—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00226	0.0106	CbGpPWpGaD
Nefazodone—Prochlorperazine—DRD2—nicotine dependence	0.00225	0.0925	CrCbGaD
Nefazodone—SLC6A3—Transmission across Chemical Synapses—CHRNA6—nicotine dependence	0.00224	0.0105	CbGpPWpGaD
Nefazodone—Hypersensitivity—Varenicline—nicotine dependence	0.00217	0.00289	CcSEcCtD
Nefazodone—HTR2A—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00215	0.0101	CbGpPWpGaD
Nefazodone—Asthenia—Varenicline—nicotine dependence	0.00212	0.00281	CcSEcCtD
Nefazodone—ADRA1A—Amine ligand-binding receptors—DRD2—nicotine dependence	0.0021	0.00987	CbGpPWpGaD
Nefazodone—Pruritus—Varenicline—nicotine dependence	0.00209	0.00277	CcSEcCtD
Nefazodone—Fluphenazine—DRD2—nicotine dependence	0.00204	0.0836	CrCbGaD
Nefazodone—HTR1A—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00202	0.00947	CbGpPWpGaD
Nefazodone—Diarrhoea—Varenicline—nicotine dependence	0.00202	0.00268	CcSEcCtD
Nefazodone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00199	0.00932	CbGpPWpGaD
Nefazodone—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00196	0.00919	CbGpPWpGaD
Nefazodone—ADRA2A—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00195	0.00917	CbGpPWpGaD
Nefazodone—Dizziness—Varenicline—nicotine dependence	0.00195	0.00259	CcSEcCtD
Nefazodone—Vomiting—Varenicline—nicotine dependence	0.00187	0.00249	CcSEcCtD
Nefazodone—Rash—Varenicline—nicotine dependence	0.00186	0.00247	CcSEcCtD
Nefazodone—Dermatitis—Varenicline—nicotine dependence	0.00186	0.00247	CcSEcCtD
Nefazodone—Headache—Varenicline—nicotine dependence	0.00185	0.00246	CcSEcCtD
Nefazodone—SLC6A3—Neuronal System—CHRNB3—nicotine dependence	0.00181	0.00849	CbGpPWpGaD
Nefazodone—CYP3A7—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00177	0.00828	CbGpPWpGaD
Nefazodone—Nausea—Varenicline—nicotine dependence	0.00175	0.00233	CcSEcCtD
Nefazodone—HTR1A—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00173	0.00812	CbGpPWpGaD
Nefazodone—SLC6A3—Neuronal System—CHRNA6—nicotine dependence	0.00172	0.00805	CbGpPWpGaD
Nefazodone—CYP3A7—Biological oxidations—CYP2A7—nicotine dependence	0.00166	0.00781	CbGpPWpGaD
Nefazodone—SLC6A4—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00166	0.00778	CbGpPWpGaD
Nefazodone—CYP3A7—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00164	0.0077	CbGpPWpGaD
Nefazodone—Trifluoperazine—DRD2—nicotine dependence	0.00163	0.0669	CrCbGaD
Nefazodone—SLC6A3—Transmission across Chemical Synapses—GABRA4—nicotine dependence	0.00162	0.00759	CbGpPWpGaD
Nefazodone—Perphenazine—DRD2—nicotine dependence	0.00161	0.0661	CrCbGaD
Nefazodone—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00161	0.00755	CbGpPWpGaD
Nefazodone—ADRA2A—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00159	0.00744	CbGpPWpGaD
Nefazodone—Quetiapine—DRD2—nicotine dependence	0.00158	0.0648	CrCbGaD
Nefazodone—SLC6A3—Transmission across Chemical Synapses—CHRNB4—nicotine dependence	0.00155	0.00728	CbGpPWpGaD
Nefazodone—SLC6A4—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00151	0.00706	CbGpPWpGaD
Nefazodone—HTR2A—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.0015	0.00702	CbGpPWpGaD
Nefazodone—SLC6A3—Transmission across Chemical Synapses—CHRNA5—nicotine dependence	0.00144	0.00677	CbGpPWpGaD
Nefazodone—SLC6A4—Circadian rythm related genes—CHRNB2—nicotine dependence	0.00135	0.00635	CbGpPWpGaD
Nefazodone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.0013	0.00609	CbGpPWpGaD
Nefazodone—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00128	0.00601	CbGpPWpGaD
Nefazodone—CYP3A5—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00128	0.00599	CbGpPWpGaD
Nefazodone—SLC6A3—Neuronal System—GABRA4—nicotine dependence	0.00124	0.00582	CbGpPWpGaD
Nefazodone—HTR1A—GPCR ligand binding—TAS2R16—nicotine dependence	0.00122	0.00573	CbGpPWpGaD
Nefazodone—HTR2C—GPCR ligand binding—TAS2R16—nicotine dependence	0.00122	0.0057	CbGpPWpGaD
Nefazodone—CYP3A5—Biological oxidations—CYP2A7—nicotine dependence	0.0012	0.00564	CbGpPWpGaD
Nefazodone—SLC6A3—Neuronal System—CHRNB4—nicotine dependence	0.00119	0.00558	CbGpPWpGaD
Nefazodone—CYP3A5—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00119	0.00556	CbGpPWpGaD
Nefazodone—SLC6A3—Transmission across Chemical Synapses—CHRNA3—nicotine dependence	0.00118	0.00552	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—TAS2R16—nicotine dependence	0.00116	0.00546	CbGpPWpGaD
Nefazodone—HTR1A—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00116	0.00542	CbGpPWpGaD
Nefazodone—SLC6A3—Neuronal System—CHRNA5—nicotine dependence	0.00111	0.00518	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—TAS2R16—nicotine dependence	0.00106	0.00495	CbGpPWpGaD
Nefazodone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00105	0.00494	CbGpPWpGaD
Nefazodone—HTR1A—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00105	0.00492	CbGpPWpGaD
Nefazodone—SLC6A3—Transmission across Chemical Synapses—CHRNB2—nicotine dependence	0.00104	0.00486	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—TAS2R16—nicotine dependence	0.00103	0.00485	CbGpPWpGaD
Nefazodone—SLC6A4—Circadian rythm related genes—DRD2—nicotine dependence	0.001	0.00469	CbGpPWpGaD
Nefazodone—HTR2A—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.000998	0.00468	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—TAS2R16—nicotine dependence	0.000961	0.00451	CbGpPWpGaD
Nefazodone—SLC6A3—Transmission across Chemical Synapses—CHRNA4—nicotine dependence	0.00094	0.00441	CbGpPWpGaD
Nefazodone—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000907	0.00426	CbGpPWpGaD
Nefazodone—HTR2A—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.000906	0.00425	CbGpPWpGaD
Nefazodone—SLC6A3—Neuronal System—CHRNA3—nicotine dependence	0.000901	0.00423	CbGpPWpGaD
Nefazodone—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000855	0.00401	CbGpPWpGaD
Nefazodone—HTR1A—G alpha (i) signalling events—OPRM1—nicotine dependence	0.000851	0.00399	CbGpPWpGaD
Nefazodone—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000844	0.00396	CbGpPWpGaD
Nefazodone—HTR1A—cardiovascular system—nicotine dependence	0.00081	0.0779	CbGeAlD
Nefazodone—SLC6A3—Neuronal System—CHRNB2—nicotine dependence	0.000793	0.00372	CbGpPWpGaD
Nefazodone—HTR1A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00079	0.00371	CbGpPWpGaD
Nefazodone—HTR2C—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000786	0.00369	CbGpPWpGaD
Nefazodone—SLC6A3—midbrain—nicotine dependence	0.000777	0.0747	CbGeAlD
Nefazodone—SLC6A2—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000753	0.00353	CbGpPWpGaD
Nefazodone—ADRA1B—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000752	0.00353	CbGpPWpGaD
Nefazodone—HTR2C—midbrain—nicotine dependence	0.000751	0.0722	CbGeAlD
Nefazodone—ADRA1A—cardiovascular system—nicotine dependence	0.000746	0.0718	CbGeAlD
Nefazodone—SLC6A3—Neuronal System—CHRNA4—nicotine dependence	0.00072	0.00338	CbGpPWpGaD
Nefazodone—SLC6A4—midbrain—nicotine dependence	0.000712	0.0685	CbGeAlD
Nefazodone—HTR1A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000691	0.00324	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000687	0.00322	CbGpPWpGaD
Nefazodone—HTR2A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000682	0.0032	CbGpPWpGaD
Nefazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000677	0.00317	CbGpPWpGaD
Nefazodone—HTR2C—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000673	0.00316	CbGpPWpGaD
Nefazodone—ADRA2A—G alpha (i) signalling events—OPRM1—nicotine dependence	0.000669	0.00314	CbGpPWpGaD
Nefazodone—ADRA1A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000668	0.00313	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000667	0.00313	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000658	0.00309	CbGpPWpGaD
Nefazodone—ADRA1B—brain—nicotine dependence	0.000652	0.0627	CbGeAlD
Nefazodone—ADRA1B—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000644	0.00302	CbGpPWpGaD
Nefazodone—HTR1A—midbrain—nicotine dependence	0.000632	0.0608	CbGeAlD
Nefazodone—HTR1A—Signaling by GPCR—TAS2R16—nicotine dependence	0.000627	0.00294	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—TAS2R16—nicotine dependence	0.000624	0.00293	CbGpPWpGaD
Nefazodone—ADRA2A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000621	0.00291	CbGpPWpGaD
Nefazodone—HTR1A—G alpha (i) signalling events—DRD2—nicotine dependence	0.000615	0.00289	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—TAS2R16—nicotine dependence	0.000597	0.0028	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000597	0.0028	CbGpPWpGaD
Nefazodone—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000593	0.00278	CbGpPWpGaD
Nefazodone—HTR2A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000585	0.00274	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000584	0.00274	CbGpPWpGaD
Nefazodone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000572	0.00269	CbGpPWpGaD
Nefazodone—HTR1A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000571	0.00268	CbGpPWpGaD
Nefazodone—HTR2C—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000568	0.00266	CbGpPWpGaD
Nefazodone—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000559	0.00262	CbGpPWpGaD
Nefazodone—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000552	0.00259	CbGpPWpGaD
Nefazodone—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000544	0.00255	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000543	0.00255	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—FGD1—nicotine dependence	0.000542	0.00254	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—TAS2R16—nicotine dependence	0.000542	0.00254	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—FGD1—nicotine dependence	0.000539	0.00253	CbGpPWpGaD
Nefazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000532	0.00249	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—TAS2R16—nicotine dependence	0.000531	0.00249	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—FGD1—nicotine dependence	0.000516	0.00242	CbGpPWpGaD
Nefazodone—HTR1A—GPCR ligand binding—OPRM1—nicotine dependence	0.000515	0.00242	CbGpPWpGaD
Nefazodone—HTR2C—GPCR ligand binding—OPRM1—nicotine dependence	0.000513	0.0024	CbGpPWpGaD
Nefazodone—HTR2A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000493	0.00231	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—TAS2R16—nicotine dependence	0.000493	0.00231	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—FGD1—nicotine dependence	0.000492	0.00231	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—OPRM1—nicotine dependence	0.000491	0.0023	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—FGD1—nicotine dependence	0.00049	0.0023	CbGpPWpGaD
Nefazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000489	0.00229	CbGpPWpGaD
Nefazodone—SLC6A3—brain—nicotine dependence	0.000488	0.047	CbGeAlD
Nefazodone—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000487	0.00228	CbGpPWpGaD
Nefazodone—ADRA2A—G alpha (i) signalling events—DRD2—nicotine dependence	0.000484	0.00227	CbGpPWpGaD
Nefazodone—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000483	0.00227	CbGpPWpGaD
Nefazodone—HTR2A—cardiovascular system—nicotine dependence	0.000482	0.0464	CbGeAlD
Nefazodone—HTR2C—brain—nicotine dependence	0.000472	0.0454	CbGeAlD
Nefazodone—ADRA1B—Signaling by GPCR—FGD1—nicotine dependence	0.000469	0.0022	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—FGD1—nicotine dependence	0.000468	0.0022	CbGpPWpGaD
Nefazodone—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000466	0.00219	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—FGD1—nicotine dependence	0.000459	0.00215	CbGpPWpGaD
Nefazodone—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000449	0.00211	CbGpPWpGaD
Nefazodone—SLC6A4—brain—nicotine dependence	0.000447	0.043	CbGeAlD
Nefazodone—HTR2A—GPCR ligand binding—OPRM1—nicotine dependence	0.000445	0.00209	CbGpPWpGaD
Nefazodone—ADRA2A—midbrain—nicotine dependence	0.000443	0.0426	CbGeAlD
Nefazodone—ADRA1A—GPCR ligand binding—OPRM1—nicotine dependence	0.000436	0.00204	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—FGD1—nicotine dependence	0.000426	0.002	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—FGD1—nicotine dependence	0.000425	0.00199	CbGpPWpGaD
Nefazodone—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000423	0.00198	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—FGD1—nicotine dependence	0.000416	0.00195	CbGpPWpGaD
Nefazodone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000414	0.00194	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—OPRM1—nicotine dependence	0.000405	0.0019	CbGpPWpGaD
Nefazodone—HTR1A—brain—nicotine dependence	0.000397	0.0382	CbGeAlD
Nefazodone—SLC6A2—brain—nicotine dependence	0.000394	0.0379	CbGeAlD
Nefazodone—ADRA2A—Signaling by GPCR—FGD1—nicotine dependence	0.000387	0.00181	CbGpPWpGaD
Nefazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000385	0.0018	CbGpPWpGaD
Nefazodone—HTR2A—midbrain—nicotine dependence	0.000377	0.0362	CbGeAlD
Nefazodone—HTR1A—GPCR ligand binding—DRD2—nicotine dependence	0.000373	0.00175	CbGpPWpGaD
Nefazodone—HTR2C—GPCR ligand binding—DRD2—nicotine dependence	0.000371	0.00174	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TAS2R16—nicotine dependence	0.000371	0.00174	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TAS2R16—nicotine dependence	0.000369	0.00173	CbGpPWpGaD
Nefazodone—ADRA1A—brain—nicotine dependence	0.000366	0.0352	CbGeAlD
Nefazodone—ADRA1B—GPCR ligand binding—DRD2—nicotine dependence	0.000355	0.00166	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TAS2R16—nicotine dependence	0.000353	0.00166	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000331	0.00155	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—DRD2—nicotine dependence	0.000322	0.00151	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TAS2R16—nicotine dependence	0.00032	0.0015	CbGpPWpGaD
Nefazodone—ABCB1—cardiovascular system—nicotine dependence	0.000316	0.0304	CbGeAlD
Nefazodone—ADRA1A—GPCR ligand binding—DRD2—nicotine dependence	0.000315	0.00148	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TAS2R16—nicotine dependence	0.000313	0.00147	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—DRD2—nicotine dependence	0.000293	0.00137	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TAS2R16—nicotine dependence	0.000291	0.00137	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—OPRM1—nicotine dependence	0.000291	0.00137	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—FGD1—nicotine dependence	0.000291	0.00136	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—OPRM1—nicotine dependence	0.00029	0.00136	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—FGD1—nicotine dependence	0.000289	0.00136	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—CYP2A7—nicotine dependence	0.000285	0.00133	CbGpPWpGaD
Nefazodone—ADRA2A—brain—nicotine dependence	0.000278	0.0268	CbGeAlD
Nefazodone—ADRA1B—GPCR downstream signaling—OPRM1—nicotine dependence	0.000277	0.0013	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—FGD1—nicotine dependence	0.000277	0.0013	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—OPRM1—nicotine dependence	0.000264	0.00124	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—OPRM1—nicotine dependence	0.000263	0.00123	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—AKR1B10—nicotine dependence	0.000257	0.0012	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—AKR1B10—nicotine dependence	0.000256	0.0012	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—OPRM1—nicotine dependence	0.000252	0.00118	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—OPRM1—nicotine dependence	0.000252	0.00118	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—FGD1—nicotine dependence	0.000251	0.00118	CbGpPWpGaD
Nefazodone—ABCB1—midbrain—nicotine dependence	0.000247	0.0237	CbGeAlD
Nefazodone—ADRA1A—GPCR downstream signaling—OPRM1—nicotine dependence	0.000246	0.00116	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—FGD1—nicotine dependence	0.000246	0.00115	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—AKR1B10—nicotine dependence	0.000245	0.00115	CbGpPWpGaD
Nefazodone—HTR2A—brain—nicotine dependence	0.000237	0.0228	CbGeAlD
Nefazodone—ADRA2A—GPCR downstream signaling—OPRM1—nicotine dependence	0.000229	0.00107	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—FGD1—nicotine dependence	0.000229	0.00107	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—OPRM1—nicotine dependence	0.000228	0.00107	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CYP2A7—nicotine dependence	0.000224	0.00105	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—OPRM1—nicotine dependence	0.000224	0.00105	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—AKR1B10—nicotine dependence	0.000222	0.00104	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—AKR1B10—nicotine dependence	0.000217	0.00102	CbGpPWpGaD
Nefazodone—CYP2D6—brain—nicotine dependence	0.000216	0.0207	CbGeAlD
Nefazodone—HTR1A—GPCR downstream signaling—DRD2—nicotine dependence	0.000211	0.000988	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—DRD2—nicotine dependence	0.000209	0.000983	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—OPRM1—nicotine dependence	0.000208	0.000975	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CYP2A7—nicotine dependence	0.000206	0.000965	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AKR1B10—nicotine dependence	0.000202	0.000947	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—DRD2—nicotine dependence	0.000201	0.000941	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—DRD2—nicotine dependence	0.000191	0.000897	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—DRD2—nicotine dependence	0.00019	0.000892	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—DRD2—nicotine dependence	0.000182	0.000854	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—DRD2—nicotine dependence	0.000182	0.000853	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—WASF2—nicotine dependence	0.000181	0.000849	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—WASF2—nicotine dependence	0.00018	0.000845	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—DRD2—nicotine dependence	0.000178	0.000835	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—WASF1—nicotine dependence	0.000174	0.000814	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—WASF1—nicotine dependence	0.000173	0.00081	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—WASF2—nicotine dependence	0.000172	0.000808	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—DRD2—nicotine dependence	0.000165	0.000776	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—WASF1—nicotine dependence	0.000165	0.000775	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—DRD2—nicotine dependence	0.000165	0.000775	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—DRD2—nicotine dependence	0.000162	0.000759	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—WASF2—nicotine dependence	0.000156	0.000733	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—OPRM1—nicotine dependence	0.000156	0.000733	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—OPRM1—nicotine dependence	0.000155	0.000729	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CYP2A7—nicotine dependence	0.000155	0.000728	CbGpPWpGaD
Nefazodone—ABCB1—brain—nicotine dependence	0.000155	0.0149	CbGeAlD
Nefazodone—ADRA1A—Signaling Pathways—WASF2—nicotine dependence	0.000153	0.000718	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—DRD2—nicotine dependence	0.00015	0.000705	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—WASF1—nicotine dependence	0.00015	0.000703	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—OPRM1—nicotine dependence	0.000149	0.000698	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—WASF1—nicotine dependence	0.000147	0.000688	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000146	0.000686	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—WASF2—nicotine dependence	0.000142	0.000667	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—WASF1—nicotine dependence	0.000136	0.00064	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—OPRM1—nicotine dependence	0.000135	0.000633	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—OPRM1—nicotine dependence	0.000132	0.00062	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—OPRM1—nicotine dependence	0.000123	0.000576	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—DRD2—nicotine dependence	0.000113	0.00053	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—DRD2—nicotine dependence	0.000112	0.000527	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—DRD2—nicotine dependence	0.000108	0.000505	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—DRD2—nicotine dependence	9.76e-05	0.000458	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP2A7—nicotine dependence	9.56e-05	0.000449	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—DRD2—nicotine dependence	9.55e-05	0.000448	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—DRD2—nicotine dependence	8.88e-05	0.000416	CbGpPWpGaD
